MedPath

Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)

The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and/or Fracture: A Nation-wide Population Based Study

Withdrawn
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2019-12-13
Last Posted Date
2020-06-01
Lead Sponsor
Pfizer
Registration Number
NCT04198844
Locations
🇰🇷

Pfizer Investigational Site, Seoul, Korea, Republic of

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Phase 3
Terminated
Conditions
Aortic Valve Disease
Aortic Valve Stenosis
Aortic Valve Failure
Interventions
Device: On-X Aortic Mechanical Valve
First Posted Date
2019-10-29
Last Posted Date
2024-03-20
Lead Sponsor
Artivion Inc.
Target Recruit Count
863
Registration Number
NCT04142658
Locations
🇺🇸

Stanford University Medical Center, Palo Alto, California, United States

🇺🇸

Piedmont Atlanta Hospital, Atlanta, Georgia, United States

🇺🇸

Northwestern Memorial Hospital, Chicago, Illinois, United States

and more 59 locations

Safety and Efficacy of Edoxaban in Thoracoscopic Ablation

Not Applicable
Completed
Conditions
Atrial Fibrillation
Anticoagulants and Bleeding Disorders
Interventions
First Posted Date
2019-10-10
Last Posted Date
2020-08-03
Lead Sponsor
Samsung Medical Center
Target Recruit Count
60
Registration Number
NCT04121767
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

AntiCoagulants and COGnition

Phase 4
Conditions
Nonvalvular Atrial Fibrillation
Interventions
First Posted Date
2019-08-29
Last Posted Date
2022-07-27
Lead Sponsor
University Hospital, Angers
Target Recruit Count
48
Registration Number
NCT04073316
Locations
🇫🇷

Angers University Hospital, Angers, France

Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study

Phase 3
Recruiting
Conditions
May-Thurner Syndrome
Interventions
First Posted Date
2019-08-26
Last Posted Date
2024-04-18
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
224
Registration Number
NCT04067505
Locations
🇨🇳

Anhui Provincial Hospital, Hefei, Anhui, China

🇨🇳

Shanghai 5th People's Hospital, Shanghai, Shanghai, China

🇨🇳

Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China

and more 6 locations

Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters

Phase 3
Recruiting
Conditions
Venous Thromboembolism
Interventions
First Posted Date
2019-08-26
Last Posted Date
2024-04-18
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
200
Registration Number
NCT04066764
Locations
🇨🇳

Anhui Provincial Hospital, Hefei, Anhui, China

🇨🇳

Yantai Yuhuangding Hospital, Yantai, Shangdong, China

🇨🇳

Shanghai 5th People's Hospital, Shanghai, Shanghai, China

and more 4 locations

Dabigatran for Mitral Stenosis Atrial Fibrillation

Phase 4
Recruiting
Conditions
Atrial Fibrillation
Mitral Stenosis
Interventions
First Posted Date
2019-08-05
Last Posted Date
2024-02-02
Lead Sponsor
The University of Hong Kong
Target Recruit Count
370
Registration Number
NCT04045093
Locations
🇭🇰

Queen Mary Hospital, Hong Kong, Hong Kong

DOAC Versus VKA After Cardiac Surgery

Phase 2
Withdrawn
Conditions
Anticoagulant-induced Bleeding
Interventions
First Posted Date
2019-06-28
Last Posted Date
2023-03-13
Lead Sponsor
Laval University
Registration Number
NCT04002011

Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis

Phase 2
Completed
Conditions
Atrial Fibrillation
End Stage Renal Failure on Dialysis
Interventions
Other: No oral anticoagulation
First Posted Date
2019-06-17
Last Posted Date
2023-06-22
Lead Sponsor
Unity Health Toronto
Target Recruit Count
151
Registration Number
NCT03987711
Locations
🇦🇺

Prince of Wales Hospital, Randwick, New South Wales, Australia

🇦🇺

Royal North Shore Hospital, Saint Leonards, New South Wales, Australia

🇨🇦

Health Sciences North, Sudbury, Ontario, Canada

and more 25 locations

RIvoraxaban in Mitral Stenosis

Phase 3
Terminated
Conditions
Mitral Stenosis
Anticoagulant Adverse Reaction
Rheumatic Heart Disease
Atrial Fibrillation
Interventions
First Posted Date
2019-04-24
Last Posted Date
2021-08-19
Lead Sponsor
Rajaie Cardiovascular Medical and Research Center
Target Recruit Count
40
Registration Number
NCT03926156
Locations
🇮🇷

Rajaie Cardiovascular Medical and Research Center, Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath